StreetInsider.com News Articles

Integra LifeSciences (IART) PT Lowered to $14 at BMO Capital

Thu, 22 Oct 2026 10:11:48 -0400

BMO Capital analyst Vik Chopra lowered the price target on Integra LifeSciences (NASDAQ: IART) to $14.00 (from $15.00) while maintaining a Market Perform rating.

Integra LifeSciences (IART) PT Lowered to $14 at JPMorgan

Thu, 22 Oct 2026 09:01:14 -0400

JPMorgan analyst Robbie Marcus lowered the price target on Integra LifeSciences (NASDAQ: IART) to $14.00 (from $17.00) while maintaining a Underweight rating.

Integra LifeSciences (IART) PT Lowered to $13 at Wells Fargo

Thu, 22 Oct 2026 07:28:46 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Integra LifeSciences (NASDAQ: IART) to $13.00 (from $15.00) while maintaining a Equal Weight rating.

Integra LifeSciences (IART) PT Lowered to $22 at Citizens on Specialty Surgical Business Headwinds

Thu, 22 Oct 2026 05:13:33 -0400

Citizens analyst David Turkaly lowered the price target on Integra LifeSciences (NASDAQ: IART) to $22.00 (from $25.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating though lower our price target to $22 from $25 on shares of Integra LifeSciences Holdings following the full release of 3Q26 operating results. Recall that earlier this month Integra had pre-announced quarterly revenue of $410–$412 mln (~1% miss at the midpoint) and quarterly EPS of $0.55–$0.59 (~3% below Street). The preannouncement also included a reduction to FY26 guidance due to: 1) updated expectations from flooding at the company's facility

Integra LifeSciences (IART) PT Lowered to $22 at Citizens on Specialty Surgical Business Headwinds

Thu, 22 Oct 2026 05:13:33 -0400

Citizens analyst David Turkaly lowered the price target on Integra LifeSciences (NASDAQ: IART) to $22.00 (from $25.00) while maintaining a Market Outperform rating.

Integra LifeSciences (IART) Tops Q3 EPS by 3c; offers guidance

Wed, 21 Oct 2026 16:45:55 -0400

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.59, $0.03 better than the analyst estimate of $0.56. Revenue for the quarter came in at $411.2 million versus the consensus estimate of $414.25 million.

GUIDANCE:

Integra LifeSciences sees Q4 2026 EPS of $0.61-$0.71, versus the consensus of $0.73. Integra LifeSciences sees Q4 2026 revenue of $413-433 million, versus the consensus of $432.21 million.

Integra LifeSciences sees FY2026 EPS of $2.30-$2.40, versus the consensus of $2.38. Integra LifeSciences sees FY2026 revenue of $1.634-1.654 billion, versus the consensus of $1.66 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

Integra LifeSciences (IART) Tops Q3 EPS by 3c; offers guidance

Wed, 21 Oct 2026 16:45:55 -0400

GUIDANCE:

Integra LifeSciences sees Q4 2026 EPS of $0.61-$0.71, versus the consensus of $0.73. Integra LifeSciences sees Q4 2026 revenue of $413-433 million, versus the consensus of $432.21 million.

Integra LifeSciences sees FY2026 EPS of $2.30-$2.40, versus the consensus of $2.38. Integra LifeSciences sees FY2026 revenue of $1.634-1.654 billion, versus the consensus of $1.66 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

Integra LifeSciences (IART) PT Lowered to $14 at Citi

Wed, 21 Oct 2026 15:25:33 -0400

Citi analyst Joanne Wuensch lowered the price target on Integra LifeSciences (NASDAQ: IART) to $14.00 (from $15.00) while maintaining a Neutral rating.

Form 8-K INTEGRA LIFESCIENCES For: Oct 21

Wed, 21 Oct 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20261021/27212597.html

Integra LifeSciences Reports Third Quarter 2026 Financial Results

Wed, 21 Oct 2026 06:00:00 -0400

PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.

Third Quarter 2026 Highlights

Third quarter revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year. Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility.
Third quarter GAAP earnings per diluted share of $0.19, compared to $(0.07) in the

Integra LifeSciences Reports Third Quarter 2026 Financial Results

Wed, 21 Oct 2026 06:00:00 -0400

Third Quarter 2026 Highlights

Third quarter revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year. Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility.
Third quarter GAAP earnings per diluted share of $0.19, compared to $(0.07) in the

Integra LifeSciences closes $450M notes offering and refinances debt

Mon, 19 Oct 2026 16:32:19 -0400

Integra LifeSciences Holdings Corporation (NASDAQ: IART) has completed a private offering of $450 million in aggregate principal amount of 9.500% senior secured notes due 2033, according to a press release from the Princeton, N.J.-based company.

Integra also amended and restated its existing credit facility, bringing the total size to approximately $1.65 billion. The restructured credit facility consists of a $600 million senior secured revolving credit facility with a five-year maturity, a $600 million senior secured term loan A facility with a five-year maturity, and a $450 million senior secured term loan B facility with a seven-year maturity.

The notes are general senior

Form 8-K INTEGRA LIFESCIENCES For: Oct 19

Mon, 19 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261019/27204147.html

Integra Announces Completion of Refinancing Transactions

Mon, 19 Oct 2026 16:05:00 -0400

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). In addition, Integra announced today that it has amended and restated its existing credit facility, with an overall size of approximately $1.65 billion consisting of (i) a $600 million senior secured revolving credit facility with a five year maturity, (ii) a $600 million senior secured term loan A facility with a five year maturity and (iii) a $450 million senior

Integra Announces Completion of Refinancing Transactions

Mon, 19 Oct 2026 16:05:00 -0400

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

Fri, 16 Oct 2026 08:39:00 -0400

PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California.

At this year's meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System.

Additionally, Integra is a sponsor of

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

Fri, 16 Oct 2026 08:39:00 -0400

Additionally, Integra is a sponsor of

Integra LifeSciences (IART) PT Lowered to $15 at Truist Securities

Wed, 14 Oct 2026 07:00:09 -0400

Truist Securities analyst Richard Newitter lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $19.00) while maintaining a Hold rating.

Form 3 INTEGRA LIFESCIENCES For: Oct 01 Filed by: Caruso Andrea B

Tue, 13 Oct 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20261013/27181888.html

Form 8-K INTEGRA LIFESCIENCES For: Oct 09

Fri, 09 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261009/27172385.html

Integra LifeSciences prices $450M in senior secured notes

Fri, 09 Oct 2026 17:22:29 -0400

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced the pricing of $450 million in aggregate principal of 9.500% senior secured notes due 2033, according to a press release from the Princeton, N.J.-based company.

The notes will serve as general senior secured obligations of the company, guaranteed by its wholly-owned domestic subsidiaries that are guarantors under its existing senior secured credit facilities. The sale is expected to close on or about October 19, 2026, subject to customary closing conditions.

The company intends to use the net proceeds, together with borrowings under new credit facilities, to refinance its existing credit facilities and cover related fees

Integra Announces Pricing of Senior Secured Notes

Fri, 09 Oct 2026 17:22:00 -0400

PRINCETON, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the “Company”) today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured credit facilities. The sale of the Notes is expected to close on or about October 19, 2026, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering of Notes,

Integra Announces Pricing of Senior Secured Notes

Fri, 09 Oct 2026 17:22:00 -0400

The Company intends to use the net proceeds from the offering of Notes,

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

Tue, 06 Oct 2026 08:30:00 -0400

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required,

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

Tue, 06 Oct 2026 08:30:00 -0400